BrainStorm announces positive results from ALS study

BrainStorm Cell Therapeutics recently released results of a study of NurOwn in patients with Amyotrophic Lateral Sclerosis (ALS) that found NurOwn was safe and well-tolerated with clear evidence of clinically meaningful benefit.
  
"We are very encouraged by these Phase 2 data that show that NurOwn cell therapy is safe and that a single administration produces a transient and clinically meaningful beneficial response in terms of both the ALS-FRS-R rating scale and CSF biomarkers," Robert Brown, professor and chair of neurology at the University of Massachusetts Medical Center and Medical School, said. "These exciting findings clearly indicate that it is appropriate to conduct a longer study with repetitive dosing."
  
The study was conducted as a randomized, double-blind, placebo controlled, phase 2 study on 48 people affected by ALS in the U.S.

"After almost thirty years of conducting clinical studies in ALS I am personally very encouraged and excited by the trial results." Anthony Windebank professor of neurology, said. "There are positive efficacy signals with clear indications to proceed to the next phase. We at Mayo clinic will be eager to move ahead with that as soon as possible."